CTMX analyst estimates
CytomX Therapeutics (CTMX) analyst ratings, the average price target and its range, and every firm's latest call.
CTMX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| May 19, 2026 | Wolfe Research | CytomX Therapeutics initiated with an Outperform at Wolfe Research | $6.00 |
| May 11, 2026 | H.C. Wainwright | CytomX Therapeutics price target lowered to $11 from $17 at H.C. Wainwright | $11.00 |
| Mar 18, 2026 | Jefferies | CytomX Therapeutics (CTMX) PT Raised to $16 at Jefferies: 'buying opportunity here' | $16.00 |
| Mar 16, 2026 | Oppenheimer | CytomX Therapeutics (CTMX) PT Raised to $12 at Oppenheimer | $12.00 |
| Feb 4, 2026 | Barclays | CytomX Therapeutics price target raised to $10 from $8 at Barclays | $10.00 |
| Jan 20, 2026 | Barclays | CytomX Therapeutics price target raised to $8 from $6 at Barclays | $8.00 |
| Jan 20, 2026 | Guggenheim | CytomX Therapeutics initiated with a Buy at Guggenheim | $10.00 |
| Jan 20, 2026 | Piper Sandler | CytomX Therapeutics price target raised to $10 from $6.50 at Piper Sandler | $10.00 |
| Oct 21, 2025 | Barclays | CytomX Therapeutics price target raised to $6 from $3.50 at Barclays | $6.00 |
| Sep 16, 2025 | Barclays | CytomX Therapeutics assumed with an Overweight at Barclays | $3.50 |
| Jul 31, 2025 | Oppenheimer | CytomX Therapeutics initiated with an Outperform at Oppenheimer | $7.00 |
| Nov 8, 2024 | Piper Sandler | CytomX Therapeutics (CTMX) PT Lowered to $3.25 at Piper Sandler | $3.25 |
| Nov 8, 2024 | BMO Capital | CytomX Therapeutics (CTMX) PT Raised to $3.68 at BMO Capital | $3.68 |
| Aug 9, 2024 | BMO Capital | CytomX Therapeutics (CTMX) PT Lowered to $3.56 at BMO Capital | $3.56 |
| May 27, 2024 | Piper Sandler | CytomX Therapeutics upgraded to Overweight from Neutral at Piper Sandler | $3.50 |
- 8 firms rate CTMX: 8 buy, 0 hold, 0 sell.
- The average price target is $8.50 from 2 analysts, from $6.00 to $11.00.
Updated 2026-11-02 17:51 UTC